Cargando…
The human IL-15 superagonist N-803 promotes migration of virus-specific CD8+ T and NK cells to B cell follicles but does not reverse latency in ART-suppressed, SHIV-infected macaques
Despite the success of antiretroviral therapy (ART) to halt viral replication and slow disease progression, this treatment is not curative and there remains an urgent need to develop approaches to clear the latent HIV reservoir. The human IL-15 superagonist N-803 (formerly ALT-803) is a promising an...
Autores principales: | Webb, Gabriela M., Molden, Jhomary, Busman-Sahay, Kathleen, Abdulhaqq, Shaheed, Wu, Helen L., Weber, Whitney C., Bateman, Katherine B., Reed, Jason S., Northrup, Mina, Maier, Nicholas, Tanaka, Shiho, Gao, Lina, Davey, Brianna, Carpenter, Benjamin L., Axthelm, Michael K., Stanton, Jeffrey J., Smedley, Jeremy, Greene, Justin M., Safrit, Jeffrey T., Estes, Jacob D., Skinner, Pamela J., Sacha, Jonah B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7093032/ https://www.ncbi.nlm.nih.gov/pubmed/32163523 http://dx.doi.org/10.1371/journal.ppat.1008339 |
Ejemplares similares
-
Combination of CD8β Depletion and Interleukin-15 Superagonist N-803 Induces Virus Reactivation in Simian-Human Immunodeficiency Virus-Infected, Long-Term ART-Treated Rhesus Macaques
por: McBrien, Julia B., et al.
Publicado: (2020) -
Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab
with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity
against GD2(+) pediatric solid tumors and in vivo survival of xenografted
immunodeficient NSG mice
por: Chu, Yaya, et al.
Publicado: (2021) -
IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34(+) progenitor-derived NK cells
por: Van der Meer, J. M. R., et al.
Publicado: (2020) -
Correction to: IL‑15 superagonist N‑803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor‑derived NK cells
por: Van der Meer, J. M. R., et al.
Publicado: (2021) -
CITN-06: a Phase I/expansion trial of alt-803, an IL-15 superagonist, in patients with advanced melanoma
por: Margolin, Kim, et al.
Publicado: (2014)